MARKET

ADAP

ADAP

Adaptimmune Therapeutics Plc
NASDAQ
1.160
-0.130
-10.08%
After Hours: 1.180 +0.02 +1.72% 16:21 04/12 EDT
OPEN
1.200
PREV CLOSE
1.290
HIGH
1.280
LOW
1.130
VOLUME
3.07M
TURNOVER
0
52 WEEK HIGH
2.050
52 WEEK LOW
0.4200
MARKET CAP
286.32M
P/E (TTM)
-2.0484
1D
5D
1M
3M
1Y
5Y
Adaptimmune slips as Roche strategic collaboration ends
Healthcare Adaptimmune falls as Roche strategic collaboration ends Apr. 12, 2024. Adaptimmune Therapeutics struck a multi-year strategic collaboration with Roche's Genentech unit in 2021. The agreement aimed at launching cell therapies for various cancer indications using ADAP's allogeneic platform.
Seeking Alpha · 12h ago
Adaptimmune Therapeutics Says On April 10, Unit Of Co, Received Notice Of Termination Of Strategic Collaboration And License Agreement With Genentech; Termination Will Become Effective 180 Days After Date Of Receipt; As Result Of Termination, Co Not Entitled To Receive Further Milestones Or Other Payments Due After Termination Date
Benzinga · 13h ago
ADAPTIMMUNE THERAPEUTICS PLC: WILL ALSO CEASE TO HAVE ANY DEVELOPMENT OBLIGATIONS AFTER TERMINATION DATE
Reuters · 13h ago
ADAPTIMMUNE THERAPEUTICS PLC: TERMINATION WILL BECOME EFFECTIVE 180 DAYS AFTER DATE OF RECEIPT OF NOTICE OF TERMINATION
Reuters · 13h ago
Weekly Report: what happened at ADAP last week (0401-0405)?
Weekly Report · 4d ago
Adaptimmune Therapeutics Plc: [Amend]General statement of acquisition of beneficial ownership
Press release · 04/03 02:06
Weekly Report: what happened at ADAP last week (0325-0329)?
Weekly Report · 04/01 09:30
Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are up 18% this past week, but still in the red over the last three years
Adaptimmune Therapeutics plc (NASDAQ:ADAP) is up 99% in the last quarter. The share price of the company has dropped 71% over three years. In the last three years, the company saw its revenue grow by 92% per year. The company's share price could be a sign of a turning point for the company. Read on to learn about the 6 warning signs we've spotted with AdaptimmuneTherapeutics.
Simply Wall St · 03/29 10:47
More
About ADAP
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).

Webull offers Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ: ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.